论文部分内容阅读
2016年6月21日在线发表于Circulation:Cardiovascular Quality Outcomes的一项研究结果表明,使用维生素K拮抗剂(VKA)的心房颤动(AF)患者的生活质量与一般人群相似。研究牵头者荷兰格罗宁根大学医学中心的Hilde AM Kooistra指出,该研究数据提供了更多关于VKA治疗方面的新观点,并显示应用VKA 3个月后对总的生活质量并不产生负面影响。而且,还可能有助于说服有卒中风险但害怕开
A study published online June 21, 2016 in Circulation: Cardiovascular Quality Outcomes showed that patients with atrial fibrillation (AF) using vitamin K antagonists (VKA) have similar quality of life as the general population. Hilde AM Kooistra, research lead at the University of Groningen Medical Center in the Netherlands, said the data provide new insights into the treatment of VKA and show that 3 months after VKA administration did not have a negative impact on overall quality of life. Moreover, it may also help to convince a risk of stroke but be afraid of it